by admin | 20 April 2023 | News
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023 Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filing Alzheimer’s patients will be administered... by admin | 18 April 2023 | News
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal... by admin | 13 April 2023 | News
Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillion The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class... by admin | 12 April 2023 | News
NEW YORK, December 4, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating... by admin | 10 April 2023 | News
Exhibition will run from March 31st to May 21st, 2023, at Prada Rong Zhai Scientific Conference will be held on April 20th, 2023, at Prada Rong Zhai NEW YORK, April 10, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a... by admin | 4 April 2023 | News
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage Tiziana actively... by admin | 4 April 2023 | News
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke Data shows behavioral outcomes improvement at one month in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of... by admin | 31 March 2023 | News
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW YORK, March 31, 2023 — Tiziana Life Sciences Ltd. (Nasdaq:... by admin | 28 March 2023 | News
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS First Phase 2 trial employing...
by admin | 23 March 2023 | Media
March 22, 2023 Nasally Administered Monoclonal Antibody for COVID-19 Emily Harris Article Information JAMA. Published online March 22, 2023. doi:10.1001/jama.2023.4000 Treating people with mild to moderate COVID-19 infections nasally with foralumab, an anti-CD3... by admin | 22 March 2023 | News
New York, March 22, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its... by admin | 21 March 2023 | News
New York, March 21, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its... by admin | 20 March 2023 | News
New York, March 20, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its... by admin | 17 March 2023 | News
NEW YORK, March 17, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that... by admin | 17 March 2023 | News
Article entitled “New T Cell Antibody Treatment Improves Outcomes For Covid Patients” reviews the company’s first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative...
by admin | 16 March 2023 | Media
New T Cell Antibody Treatment Improves Outcomes For Covid Patients William A. Haseltine Contributor Mar 16, 2023,09:57am EDT The need for effective Covid-19 drugs is ever-expanding. Hundreds of millions, if not billions, have been infected by SARS-CoV-2 throughout the...
by admin | 16 March 2023 | Media
Nasal Foralumab Shows Promise in Regulating Inflammatory Response of COVID-19 Mar 15, 2023Ashley Gallagher, Associate Editor Study includes healthy individuals and those who had progressive multiple sclerosis with the nasally administered treatment. sdecoret /... by admin | 15 March 2023 | News
Grant of share options NEW YORK, March 15, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the grant of...
by admin | 9 March 2023 | Media
First Nasal Monoclonal Antibody Treatment for COVID-19 Shows Promise for Treating Virus, Other Diseases In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19Similar reduction in...
by admin | 9 March 2023 | Media
March 8, 2023 BWH’s investigators test Foralumab in pilot trial for Covid-19 Manufactured by Tiziana Life Sciences, Foralumab stimulates the immune system’s regulatory T cells. The investigators found evidence that Foralumab dampened the inflammatory T cell...
by admin | 9 March 2023 | Media
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19 Date: March 8, 2023 Source:... by admin | 8 March 2023 | News
Illustrates that the immunological basis of the mechanism of action for intranasal foralumab is based on increasing production of naïve-like T cells and Tregs, while simultaneously decreasing the production of effector T cells Further, highlights how intranasal... by admin | 11 January 2023 | News
NEW YORK, November 1, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer... by admin | 4 January 2023 | News
NEW YORK, January 4, 2023 — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the Investigational New Drug (IND)...
